AUTL
Price
$1.33
Change
+$0.10 (+8.13%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
359.27M
Earnings call today
ERAS
Price
$1.40
Change
+$0.17 (+13.82%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
393.77M
90 days until earnings call
Ad is loading...

AUTL vs ERAS

Header iconAUTL vs ERAS Comparison
Open Charts AUTL vs ERASBanner chart's image
Autolus Therapeutics
Price$1.33
Change+$0.10 (+8.13%)
Volume$46.12K
Capitalization359.27M
Erasca
Price$1.40
Change+$0.17 (+13.82%)
Volume$23.65K
Capitalization393.77M
AUTL vs ERAS Comparison Chart
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. ERAS commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a Buy and ERAS is a Buy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (AUTL: $1.23 vs. ERAS: $1.39)
Brand notoriety: AUTL and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 167% vs. ERAS: 96%
Market capitalization -- AUTL: $359.27M vs. ERAS: $393.77M
AUTL [@Biotechnology] is valued at $359.27M. ERAS’s [@Biotechnology] market capitalization is $393.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • AUTL’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than AUTL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 4 bullish TA indicator(s).

  • AUTL’s TA Score: 4 bullish, 4 bearish.
  • ERAS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AUTL is a better buy in the short-term than ERAS.

Price Growth

AUTL (@Biotechnology) experienced а -12.77% price change this week, while ERAS (@Biotechnology) price change was -6.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.88%. For the same industry, the average monthly price growth was +15.29%, and the average quarterly price growth was -13.75%.

Reported Earning Dates

AUTL is expected to report earnings on Jul 31, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-3.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($394M) has a higher market cap than AUTL($359M). ERAS YTD gains are higher at: -44.622 vs. AUTL (-47.660). ERAS has higher annual earnings (EBITDA): -151.33M vs. AUTL (-192.51M). AUTL has more cash in the bank: 657M vs. ERAS (319M). AUTL (52.2M) and ERAS (52.9M) have identical debt. AUTL has higher revenues than ERAS: AUTL (10.1M) vs ERAS (0).
AUTLERASAUTL / ERAS
Capitalization359M394M91%
EBITDA-192.51M-151.33M127%
Gain YTD-47.660-44.622107%
P/E RatioN/AN/A-
Revenue10.1M0-
Total Cash657M319M206%
Total Debt52.2M52.9M99%
FUNDAMENTALS RATINGS
AUTL: Fundamental Ratings
AUTL
OUTLOOK RATING
1..100
66
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AUTLERAS
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 17 days ago
83%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JATSX55.670.52
+0.94%
Janus Henderson Glb Tech and Innovt S
ESMCX14.63N/A
N/A
Invesco EQV Euro Small Company C
GBCCX14.10N/A
N/A
Gabelli Dividend Growth C
KGIIX15.03N/A
N/A
Kopernik International I
QRLVX31.16N/A
N/A
Federated Hermes MDT Large Cap Value R

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
+4.24%
CRSP - AUTL
46%
Loosely correlated
+3.29%
OCUL - AUTL
41%
Loosely correlated
-1.74%
RGNX - AUTL
41%
Loosely correlated
-8.59%
CABA - AUTL
40%
Loosely correlated
+0.87%
NTLA - AUTL
40%
Loosely correlated
+0.55%
More